Leading IT During a Pandemic: The Suite Spot

The Suite Spot is a fireside chat about all topics IT and OT. We will attempt to bring clarity to the business value of traditionally tech topics. We remove the fog of acronym war and deliver to you the value you need to make these complex technologies work for your business.

Powered by RedCircle

 

IT teams face difficult challenges every day. Add a pandemic on top, and it’s going to take special attention to best practices and strategies to achieve operational goals.

On this episode of The Suite Spot, hosts Carlos Vargas, Paul Lewis and Howard Holton provide their insights on how best to lead IT forward, even during a period of uncertainty like this one.

“I think this is the most interesting crisis we’ve had since the 1920s’ Spanish Flu,” Holton said.

In the face of that nearly unprecedented crisis, Lewis said IT organizations have been forced to adapt.

“I don’t think they have a choice but to change,” he said. “The reality is a good portion of these organizations are at home. … IT’s role has changed dramatically because of it.”

There are four major concerns related to a crisis of this magnitude that the trio dove into, including:

  • How to manage capability, meaning how organizations are going to accomplish things that traditionally required more than one person in a room
  • Resiliency and capacity, which now need to be completely re-evaluated
  • Cybersecurity in terms of both keeping the bad guys out and in locking down many more “fronts” thanks to remote work
  • Digital transformation-related projects, which will take new shapes in light of new ways of doing business

Make Sure to Subscribe to The Suite Spot to Stay Up to Date!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More